Sugi Predict

Sugi Predict / Compounds / SCHEMBL6301593

SCHEMBL6301593

SCHEMBL6301593

CCOC(=O)c1ccc(NC(C)=O)c(NCc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC8 Q9BY41 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ KMT2A Q03164 4/20 0.50
▸ LMNA P02545 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ NLRP1 Q9C000 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ MEN1 O00255 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ TRPV1 Q8NER1 1/20 0.45
▸ MAPT P10636 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650334 0.91 ALDH1A1 (0.55) HDAC1HDAC8HDAC6KMT2AALDH1A1
SCHEMBL6260654 0.89 LMNA (0.48) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6301558 0.89 KMT2A (0.48) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6301341 0.89 KMT2A (0.48) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6301182 0.89 KMT2A (0.47) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6430006 0.88 KMT2A (0.47) HDAC1HDAC8HDAC6KMT2AMAPK1
SCHEMBL6301145 0.88 KMT2A (0.47) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6301072 0.87 KMT2A (0.50) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL6303883 0.87 RAB9A (0.59) HDAC1HDAC8HDAC6KMT2ALMNA
SCHEMBL7657052 0.86 KMT2A (0.58) KMT2ALMNAALDH1A1MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869950-B1 Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 — — US disclosed
US-20050032647-A1 Mixture of herbically active material, solvent and sulfosuccinic acid compound BAYER CROPSCIENCE GMBH (DE) 2005-02-10 — — US disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 — — US disclosed
EP-1142880-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 — — EP disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 — — EP disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032647-A1 Mixture of herbically active material, solvent and sulfosuccinic acid compound STS, SCLY, SRM HDAC1 592/4885HDAC8 256/4885HDAC6 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.